Follow-Up Every Three to Four Months Patients in the maintenance phase are typically seen every three to four months, depending on the medication, insurance requirements, and clinical needs
References Jastreboff, A.M., Kaplan, L.M., Fras, J.P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M.L
Previous experience with cases like Vioxx, Zantac, talcum powder, or opioid litigation means they understand the unique challenges of suing major pharmaceutical companies
GLP-1 is also involved in multiple other physiological processes including appetite, cardiovascular function, and inflammation ( Acute Inflammation is central to in-vivo responses to a wide range of challenges including viral and bacteriological infections, and to host repair processes
You are likely eating significantly less than before, and the challenge shifts from managing side effects to ensuring adequate nutrition
Behavioral changes Patients on GLP-1s can successfully amplify their results by focusing on stress management and improved sleep quality